Antiatherothrombotic effects of dipeptidyl peptidase inhibitors (Q38195527)

30 August 2017

1 reference

title

Antiatherothrombotic effects of dipeptidyl peptidase inhibitors (English)

1 reference

30 August 2017

Mansoor Husain

3

0 references

author name string

Alison Cameron-Vendrig

series ordinal

1

1 reference

30 August 2017

Dhanwantee Mundil

series ordinal

2

1 reference

30 August 2017

1 May 2014

1 reference

Current Atherosclerosis Reports

30 August 2017

1 reference

30 August 2017

16

1 reference

30 August 2017

408

1 reference

30 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-014-0408-2

30 August 2017

0 references

cites work

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

GLP-1 receptor agonists: a clinical perspective on cardiovascular effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Postprandial triglycerides and endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Dyslipidemia in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Inflammatory process in type 2 diabetes: The role of cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Inflammation and the etiology of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Type 2 diabetes as an inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Oxidative stress-induced insulin resistance in rat skeletal muscle: role of glycogen synthase kinase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Platelet dysfunction in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Factors contributing to increased platelet reactivity in people with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0408-2

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

21 January 2018

1 reference

12 December 2020

Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus

1 reference

12 December 2020

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes

1 reference

12 December 2020

A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association

1 reference

12 December 2020

Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients

1 reference

12 December 2020

10.1007/S11883-014-0408-2

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1046197378

0 references

Fatcat ID

release_rywzbqwll5c5zg7h2wxmttzvnm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rywzbqwll5c5zg7h2wxmttzvnm

24 November 2022

mapped directly with Wikidata item

1 reference